Glenview Trust co Trims Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Glenview Trust co lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,149 shares of the specialty pharmaceutical company’s stock after selling 500 shares during the quarter. Glenview Trust co’s holdings in Jazz Pharmaceuticals were worth $511,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in JAZZ. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after purchasing an additional 48,708 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its holdings in shares of Jazz Pharmaceuticals by 8.3% in the third quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock worth $87,035,000 after purchasing an additional 59,685 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 15.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company’s stock worth $75,801,000 after purchasing an additional 83,807 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Jazz Pharmaceuticals by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company’s stock worth $58,835,000 after purchasing an additional 24,481 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JAZZ. HC Wainwright upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Morgan Stanley reiterated an “overweight” rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Finally, Royal Bank of Canada dropped their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $140.22 on Tuesday. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.44. The firm has a 50-day simple moving average of $129.88 and a two-hundred day simple moving average of $121.01. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.